We are live on
!
Find out more
SIP
Stoneridge Investment Partners Portfolio holdings
AUM
$152M
1-Year Est. Return
20.58%
This Fund
S&P 500
This Quarter
Est. Return
+0.76%
1 Year Est. Return
+20.58%
3 Year Est. Return
+44.17%
5 Year Est. Return
+32.14%
10 Year Est. Return
+92.72%
AUM
$280M
AUM Growth
+$10.8M
(+4%)
Cap. Flow
+$9.98M
Cap. Flow
% of AUM
3.57%
Top 10 Holdings %
Top 10 Hldgs %
39.43%
Holding
168
New
48
Increased
41
Reduced
29
Closed
33
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CVS Health
CVS
|
+$8.54M |
| 2 |
Chubb
CB
|
+$7.86M |
| 3 |
Citigroup
C
|
+$6.58M |
| 4 |
Fidelity National Information Services
FIS
|
+$5.57M |
| 5 |
American International
AIG
|
+$4.77M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Wells Fargo
WFC
|
+$11M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$7.56M |
| 3 |
WEC Energy
WEC
|
+$5.59M |
| 4 |
L3Harris
LHX
|
+$4.44M |
| 5 |
Zimmer Biomet
ZBH
|
+$3.81M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 36.56% |
| 2 | Financials | 11.47% |
| 3 | Industrials | 9.71% |
| 4 | Consumer Discretionary | 9.38% |
| 5 | Communication Services | 9.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ESPR
151
DELISTED
Esperion Therapeutics
ESPR
| – | – |
-117,958
| Closed | -$195K |
|
|
FARO
152
DELISTED
Faro Technologies
FARO
| – | – |
-11,398
| Closed | -$218K |
|
153
Healthcare Services Group
HCSG
$1.5B
| – | – |
-18,834
| Closed | -$210K |
|
154
Humana
HUM
$46.3B
| – | – |
-4,065
| Closed | -$1.29M |
|
|
155
L3Harris
LHX
$54B
| – | – |
-18,671
| Closed | -$4.44M |
|
156
McKesson
MCK
$103B
| – | – |
-4,999
| Closed | -$2.47M |
|
157
Organogenesis Holdings
ORGO
$239M
| – | – |
-34,105
| Closed | -$98K |
|
158
Ouster
OUST
$3.04B
| – | – |
-10,686
| Closed | -$67K |
|
159
Principal Financial Group
PFG
$24.4B
| – | – |
-30,284
| Closed | -$2.6M |
|
160
The RMR Group
RMR
$335M
| – | – |
-10,226
| Closed | -$260K |
|
161
Ross Stores
ROST
$81.7B
| – | – |
-10,543
| Closed | -$1.59M |
|
162
Telos
TLS
$302M
| – | – |
-14,218
| Closed | -$51K |
|
163
Treace Medical Concepts
TMCI
$304M
| – | – |
-16,852
| Closed | -$98K |
|
|
164
WEC Energy
WEC
$34.6B
| – | – |
-58,139
| Closed | -$5.59M |
|
|
165
Wells Fargo
WFC
$265B
| – | – |
-195,561
| Closed | -$11M |
|
166
W.R. Berkley
WRB
$26.3B
| – | – |
-61,451
| Closed | -$3.49M |
|
167
Xeris Biopharma Holdings
XERS
$1.46B
| – | – |
-15,028
| Closed | -$43K |
|
|
168
Zimmer Biomet
ZBH
$18.7B
| – | – |
-35,337
| Closed | -$3.81M |
|
Similar funds
HWM
SGM
CMMS
FHC
RHAM
II
APW
BCI
Stoneridge Investment Partners's Q4 2024 Portfolio in Review
As of Q4 2024, Stoneridge Investment Partners held 168 positions worth $280M, up 4% from $269M the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Stoneridge Investment Partners deployed $9.98M of net new capital in Q4 2024, opening 48 new positions and adding to 41 existing holdings. Its largest new stake was Chubb: 27,680 shares worth $7.65M.
By sector, the portfolio is most concentrated in Technology at 37% of assets, up from 34% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was General Motors, an estimated $3.69M trimmed.
- Stoneridge Investment Partners's largest Q4 2024 buy was Chubb: 27,680 shares worth $7.65M.
- Stoneridge Investment Partners added most to CVS Health in Q4 2024, an estimated $8.54M increase.
- Stoneridge Investment Partners's biggest Q4 2024 reduction was General Motors, cutting an estimated $3.69M.
- Stoneridge Investment Partners fully exited Wells Fargo in Q4 2024, selling an estimated $11M.
- Stoneridge Investment Partners's ten largest holdings make up 39% of its $280M portfolio in Q4 2024.
- Stoneridge Investment Partners opened 48 new positions and closed 33 in Q4 2024.
- Stoneridge Investment Partners's portfolio value rose 4% quarter-over-quarter to $280M.
Based on Stoneridge Investment Partners's 13F filing for Q4 2024, filed 28 Jan 2025.